Transcend Therapeutics discovers, develops, and delivers next-generation psychoactive medicines to work toward a world in which people no longer suffer from neuropsychiatric disease. Transcend focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have already advanced our lead compound into an approved study in PTSD, with plans to expand into depression and other indications. We already have real-world data showing that our lead product provided significant benefit in 85% of a case series of patients with PTSD and depression. In addition, we have begun the process of disseminating our preclinical and clinical data at the world's premier psychiatry conferences.
Transcend’s leadership team includes the first scientist to receive federal funding for clinical psychedelic research in 54 years; drug development executives with pivotal contributions to >20 FDA approvals and seven major biopharma exits totaling $4 billion in combined value. We are backed by AlleyCorp, an incubator and venture capital fund that has founded some of the most transformative companies in New York, including MongoDB, Business Insider, Gilt Groupe, Zola, Nomad Health, and many others. AlleyCorp incubations have collectively raised $1B+ in venture capital with an aggregate value of $30B+.
As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and patient access.
We are committed to building a diverse, inclusive and talented team, free from discrimination. If you're excited about our mission but don't meet 100% of the qualifications above, we encourage you to apply.